Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Joshi Alumkal"'
Autor:
Rebecca Smith, Moqing Liu, Tiera Liby, Nora Bayani, Elmar Bucher, Kami Chiotti, Daniel Derrick, Anne Chauchereau, Laura Heiser, Joshi Alumkal, Heidi Feiler, Peter Carroll, James E. Korkola
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our treatment of prostate cancer. Here we describe molecular characterization and drug te
Externí odkaz:
https://doaj.org/article/708df8dc657045d19f9756d95d497a15
Autor:
Liang Kee Goh, Natalia Liem, Aadhitthya Vijayaraghavan, Gengbo Chen, Pei Li Lim, Kae-Jack Tay, Michelle Chang, John Soon Wah Low, Adita Joshi, Hong Hong Huang, Emarene Kalaw, Puay Hoon Tan, Wen-Son Hsieh, Wei Peng Yong, Joshi Alumkal, Hong Gee Sim
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91666 (2014)
We aimed to identify a prostate cancer DNA hypermethylation microarray signature (denoted as PHYMA) that differentiates prostate cancer from benign prostate hyperplasia (BPH), high from low-grade and lethal from non-lethal cancers. This is a non-rand
Externí odkaz:
https://doaj.org/article/d7fee0e656a4443f97c9947f46d69f2b
Autor:
Lina Gao, Jacob Schwartzman, Angela Gibbs, Robert Lisac, Richard Kleinschmidt, Beth Wilmot, Daniel Bottomly, Ilsa Coleman, Peter Nelson, Shannon McWeeney, Joshi Alumkal
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63563 (2013)
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initial
Externí odkaz:
https://doaj.org/article/56a9fdb104c94a60960e310694613d85
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 883K, Patient disposition by treatment group. IP, investigational product; MP, mitoxantrone and prednisone. *Patient had a decrease in hemoglobin prior to administration of IP on day 1 of cycle 1. �Patient had delays to cycles prior to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37edf82e35ba58776afcdc674fe3048a
https://doi.org/10.1158/1078-0432.22446554
https://doi.org/10.1158/1078-0432.22446554
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 1418K, Forest plot of the treatment effect of rilotumumab compared with placebo on OS by covariate subgroups in the intention-to-treat analysis set. ECOG, Eastern Cooperative Oncology Group; PD, progressive disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3766820720645206b1af1000726b2fcc
https://doi.org/10.1158/1078-0432.22446551
https://doi.org/10.1158/1078-0432.22446551
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 28K, Kaplan-Meier plot of OS (A) and PFS (B) by tumor MET expression in all treatment arms combined.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea079fefe5d8acb51d694d15046811e
https://doi.org/10.1158/1078-0432.22446536
https://doi.org/10.1158/1078-0432.22446536
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 28K, Waterfall plot of the maximum change in the sum of the longest diameters of tumors from baseline in patients with evaluable tumor response per investigator assessment who received rilotumumab (A) or placebo (B). Fifteen patients in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d67077bb814fd27dcd9466b31eb26210
https://doi.org/10.1158/1078-0432.22446539.v1
https://doi.org/10.1158/1078-0432.22446539.v1
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 54K, Drug exposure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792ca1d5dc8eac4da69a34c1a78d6f1b
https://doi.org/10.1158/1078-0432.22446527
https://doi.org/10.1158/1078-0432.22446527
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 31K, Waterfall plot of the maximum change of PSA levels from baseline in patients who received rilotumumab (A) or placebo (B) in the intention-to-treat analysis set. A PSA response was defined as ≥50% decline in two consecutive PSA level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::693248e2e42820bf24bc5f192cea8ba8
https://doi.org/10.1158/1078-0432.22446542
https://doi.org/10.1158/1078-0432.22446542
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 1076K, Kaplan-Meier plot of PFS by tumor MET subgroups in the combined rilotumumab and control arms (A) and forest plot of the biomarker effect of high versus low tumor MET expression on PFS within the combined rilotumumab and control arms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::289fdacb2d39290f8d764b3485062526
https://doi.org/10.1158/1078-0432.22446548
https://doi.org/10.1158/1078-0432.22446548